Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deborah K Armstrong

Showing results (1-10 of 156) with videos related to

Pageof 16
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|May 25, 2013
New issues in systemic therapy for ovarian cancerDeborah K Armstrong
Gynecologic Oncology|December 17, 2022
AML and MDS associated with PARP inhibitor treatment of ovarian cancerDeborah K Armstrong
The Oncologist|February 3, 2004
Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicityDeborah K Armstrong
Journal of the National Comprehensive Cancer Network : JNCCN|May 23, 2018
New Therapies for Ovarian CancerDeborah K Armstrong
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 27, 2017
Research Summaries: The 11th Biennial Rivkin Center Ovarian Cancer Research SymposiumDeborah K Armstrong
The Oncologist|September 27, 2002
Relapsed ovarian cancer: challenges and management strategies for a chronic diseaseDeborah K Armstrong
Gynecologic Oncology|October 15, 2011
The "luxury" of second malignanciesDeborah K Armstrong, Kala Visvanathan
Current Pharmaceutical Design|May 18, 2012
Role of farletuzumab in epithelial ovarian carcinomaDanijela Jelovac, Deborah K Armstrong
Oncology (Williston Park, N.Y.)|June 21, 2013
Planning treatment for women with recurrent epithelial ovarian cancerEdward Tanner, Deborah K Armstrong
CA: a Cancer Journal for Clinicians|April 28, 2011
Recent progress in the diagnosis and treatment of ovarian cancerDanijela Jelovac, Deborah K Armstrong
Pageof 16

Showing results (1-10 of 156) with videos related to

Sort By:
Pageof 16
Journal of the National Comprehensive Cancer Network : JNCCN|May 25, 2013
New issues in systemic therapy for ovarian cancerDeborah K Armstrong
Gynecologic Oncology|December 17, 2022
AML and MDS associated with PARP inhibitor treatment of ovarian cancerDeborah K Armstrong
The Oncologist|February 3, 2004
Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicityDeborah K Armstrong
Journal of the National Comprehensive Cancer Network : JNCCN|May 23, 2018
New Therapies for Ovarian CancerDeborah K Armstrong
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 27, 2017
Research Summaries: The 11th Biennial Rivkin Center Ovarian Cancer Research SymposiumDeborah K Armstrong
The Oncologist|September 27, 2002
Relapsed ovarian cancer: challenges and management strategies for a chronic diseaseDeborah K Armstrong
Gynecologic Oncology|October 15, 2011
The "luxury" of second malignanciesDeborah K Armstrong, Kala Visvanathan
Current Pharmaceutical Design|May 18, 2012
Role of farletuzumab in epithelial ovarian carcinomaDanijela Jelovac, Deborah K Armstrong
Oncology (Williston Park, N.Y.)|June 21, 2013
Planning treatment for women with recurrent epithelial ovarian cancerEdward Tanner, Deborah K Armstrong
CA: a Cancer Journal for Clinicians|April 28, 2011
Recent progress in the diagnosis and treatment of ovarian cancerDanijela Jelovac, Deborah K Armstrong
Pageof 16